Sugi Predict

Sugi Predict / Compounds / SCHEMBL2365784

SCHEMBL2365784

SCHEMBL2365784

Cc1ccc(OC2CCNCC2)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HRH1 P35367 3/20 0.66
▸ HRH3 Q9Y5N1 3/20 0.49
▸ HTR2C P28335 2/20 0.48
▸ HTR2B P41595 2/20 0.48
▸ IKBKB O14920 1/20 0.47
▸ ACVR1B P36896 1/20 0.46
▸ TGFBR1 P36897 1/20 0.46
▸ ACVR1 Q04771 1/20 0.46
▸ KCNH2 Q12809 1/20 0.46
▸ ROCK1 Q13464 4/20 0.45
▸ ROCK2 O75116 1/20 0.45
▸ PRKACA P17612 1/20 0.45
▸ PRKCD Q05655 1/20 0.45
▸ PRKG1 Q13976 1/20 0.45
▸ PKN1 Q16512 1/20 0.45
▸ PKN2 Q16513 1/20 0.45
▸ AAK1 Q2M2I8 1/20 0.45
▸ CDC42BPA Q5VT25 1/20 0.45
▸ Q6ZSR9 Q6ZSR9 1/20 0.45
▸ BMP2K Q9NSY1 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL31587801 0.98 HRH1 (0.63) HRH1HRH3HTR2CHTR2BIKBKB
Hydrochloric Acid SCHEMBL23410284 0.96 HRH1 (0.61) HRH1HRH3HTR2CHTR2BIKBKB
SCHEMBL18295396 0.89 HTR2C (0.59) HRH1HTR2CHTR2BROCK1
SCHEMBL30530690 0.89 HTR2C (0.59) HRH1HTR2CHTR2BROCK1
SCHEMBL14453569 0.89 HTR2C (0.59) HRH1HTR2CHTR2BROCK1
SCHEMBL470126 0.85 ACHE (0.46) HRH1HRH3MEN1KMT2A
SCHEMBL942628 0.84 HRH1 (0.66) HRH1HRH3HTR2CIKBKBACVR1B
SCHEMBL2019376 0.83 HRH1 (0.70) HRH1HRH3IKBKBACVR1BTGFBR1
Hydrochloric Acid SCHEMBL7480710 0.82 HRH1 (0.63) HRH1HRH3HTR2CIKBKBACVR1B
SCHEMBL21139770 0.82 HRH3 (0.56) HRH1HRH3MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9951040-B2 1,3,5 -triazine based PI3K inhibitors as anticancer agents and a process for the preparation thereof COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2018-04-24 — — US claimed
US-20170342049-A1 NOVEL 1,3,5 -TRIAZINE BASED PI3K INHIBITORS AS ANTICANCER AGENTS AND A PROCESS FOR THE PREPARATION THEREOF COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2017-11-30 — — US claimed
EP-3221307-A1 NOVEL 1,3,5 -TRIAZINE BASED PI3K INHIBITORS AS ANTICANCER AGENTS AND A PROCESS FOR THE PREPARATION THEREOF Council of Scientific and Industrial Research (IN) 2017-09-27 — — EP claimed
WO-2016079760-A1 NOVEL 1,3,5 -TRIAZINE BASED PI3K INHIBITORS AS ANTICANCER AGENTS AND A PROCESS FOR THE PREPARATION THEREOF COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2016-05-26 — — WO claimed
US-8592595-B2 Preparation of (N-heterocyclyl) aryl ethers SALTIGO GMBH (DE) 2013-11-26 — — US claimed
US-20100152454-A1 PREPARATION OF (N-HETEROCYCLYL) ARYL ETHERS SALTIGO GMBH (DE) 2010-06-17 — — US claimed
EP-2179988-A1 Producing (N-heterocyclic) aryl ethers Saltigo GmbH (DE) 2010-04-28 — — EP claimed
EP-4219465-A2 PRMT5 INHIBITORS AND USES THEREOF Epizyme Inc (US) 2023-08-02 — — EP disclosed
EP-3793990-B1 ANTIBACTERIAL COMPOUNDS INFEX THERAPEUTICS LTD (GB) 2023-07-19 — — EP disclosed
US-11702388-B2 1,4-substituted piperidine derivatives 89BIO LTD (IL) 2023-07-18 — — US disclosed
US-20230062100-A1 SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION BAYER AKTIENGESELLSCHAFT (DE) 2023-03-02 — — US disclosed
EP-3498701-B1 PRMT5 INHIBITORS AND USES THEREOF EPIZYME INC (US) 2023-02-22 — — EP disclosed
EP-4065570-A1 SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION Bayer Aktiengesellschaft (DE) 2022-10-05 — — EP disclosed
WO-1987000841-A1 NEW THEOPHYLLINE DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF THIELE KURT (CH) 1987-02-12 — — WO disclosed
US-4603204-A Theophylline derivatives SIEGFRIED AKTIENGESELLSCHAFT (CH) 1986-07-29 — — US disclosed
EP-0071738-B1 THEOPHYLLINE DERIVATIVES AND PROCESS FOR THEIR PREPARATION SIEGFRIED AKTIENGESELLSCHAFT (CH) 1986-02-19 — — EP disclosed
EP-0158283-A2 Substituted 1-aminoalkylamino-4-aryloxypiperidines, a process for their preparation, intermediates thereof, and their use as medicaments HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) 1985-10-16 — — EP disclosed
US-4518713-A Analgesic substituted-1-aminoalkylamino-4-aryloxypiperidines HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) 1985-05-21 — — US disclosed
EP-0071738-A1 Theophylline derivatives and process for their preparation SIEGFRIED AKTIENGESELLSCHAFT (CH) 1983-02-16 — — EP disclosed
US-4031221-A ANALGESICS, TRANQUILIZERS, INDOLE COMPOUNDS AMERICAN HOECHST CORPORATION (US) 1977-06-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230062100-A1 SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION DGKK, DGKG, DGKA HRH1 326/4885HRH3 437/4885HTR2C 4529/4885
US-11702388-B2 1,4-substituted piperidine derivatives FASN, CES1, CPT1A HRH1 2563/4885HRH3 4067/4885HTR2C 1563/4885
US-20170342049-A1 NOVEL 1,3,5 -TRIAZINE BASED PI3K INHIBITORS AS ANTICANCER AGENTS AND A PROCESS FOR THE PREPARATION THEREOF PIK3CA, PIK3R5, PIK3CD HRH1 3298/4885HRH3 4044/4885HTR2C 3020/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.